The earnings call highlighted steady revenue growth and strategic advancements in biosimilars and Indian markets as positive aspects. However, these were offset by challenges in the U.S. generics business, decreased gross profit margins, and regulatory observations. The increase in SG&A expenses also added pressure. Overall, the positive aspects were balanced by significant lowlights.

Company Guidance -

Q2 2026

During the Q1 FY '26 earnings call of Dr. Reddy's Laboratories Limited, the company reported several key financial metrics and business updates. The firm achieved a consolidated revenue of INR 8,545 crores (USD 997 million), marking an 11% year-over-year growth. They recorded an EBITDA margin of 26.7%, slightly surpassing their 25% aspiration. However, the gross profit margin decreased by 350 basis points year-on-year to 56.9%, due primarily to price erosion in the generic segment. The R&D expenditure remained stable at INR 624 crores (USD 73 million), and SG&A expenses increased by 13% year-over-year to INR 2,565 crores (USD 299 million). The company maintained a robust balance sheet with a net cash surplus of INR 2,922 crores (USD 341 million), and the RoCE for the quarter was 22%. Dr. Reddy's also emphasized their strategic focus on the semaglutide and abatacept pipeline and noted progress in strategic collaborations and biosimilar operations.

Double-Digit Revenue Growth

Dr. Reddy's Laboratories reported a steady double-digit revenue growth of 11% year-over-year, driven by strong performance across most markets, excluding the U.S. generics business.

EBITDA Margin Exceeds Expectations

The company achieved an EBITDA margin of 26.7%, surpassing their aspiration of 25%.

Biosimilar Business Momentum

The biosimilar business gained momentum due to strategic collaboration with Alvotech for co-development, manufacturing, and commercialization of pembrolizumab.

Carbon Disclosure Project Rating

Dr. Reddy's Laboratories received an 'A' rating in the climate category from the Carbon Disclosure Project, making it the only Indian pharmaceutical company with this score.

Indian Market Performance

The India business reported double-digit growth of 11% year-on-year, driven by new products and pricing. The company maintained its position as the 10th largest player in the Indian pharmaceutical market.

Dr Reddy's Laboratories (RDY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RDY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2026 (Q2)	0.20 / -	0.178	―	―	―
Jul 23, 2025	2026 (Q1)	0.21 / 0.20	0.199	-1.01% (>-0.01)
May 09, 2025	2025 (Q4)	0.21 / 0.22	0.188	19.15% (+0.04)
Jan 23, 2025	2025 (Q3)	0.21 / 0.20	0.199	-1.01% (>-0.01)	―
Nov 05, 2024	2025 (Q2)	0.21 / 0.18	0.213	-16.43% (-0.04)	―
Jul 27, 2024	2025 (Q1)	0.19 / 0.20	0.206	-3.40% (>-0.01)	―
May 07, 2024	2024 (Q4)	0.18 / 0.19	0.14	34.29% (+0.05)	―
Jan 30, 2024	2024 (Q3)	0.18 / 0.20	0.184	8.15% (+0.02)	―
Oct 27, 2023	2024 (Q2)	0.17 / 0.21	0.162	31.48% (+0.05)	―
Jul 26, 2023	2024 (Q1)	0.15 / 0.21	0.179	15.08% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RDY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 23, 2025	$14.41	$14.60	+1.32%
May 09, 2025	$13.18	$13.40	+1.67%
Jan 23, 2025	$15.09	$14.15	-6.23%
Nov 05, 2024	$14.80	$14.61	-1.28%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dr. Reddy's Laboratories Ltd (RDY) report earnings?

Dr. Reddy's Laboratories Ltd (RDY) is schdueled to report earning on Oct 24, 2025, Before Open (Confirmed).

What is Dr. Reddy's Laboratories Ltd (RDY) earnings time?

Dr. Reddy's Laboratories Ltd (RDY) earnings time is at Oct 24, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RDY EPS forecast?

RDY EPS forecast for the fiscal quarter 2026 (Q2) is 0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing